Are you one of the millions of women
who have faced breast cancer?

If you’re currently cancer-free, consider our research study.

A study is being conducted to evaluate whether an investigational drug can reduce the risk of previously diagnosed HER-2 positive breast cancer from returning after treatment with trastuzumab. This study will enroll women who have erbB-2 (HER-2) positive breast cancer and have completed a course of prior trastuzumab treatment.

You may be able to participate in this study if you:

• Have erbB-2 (HER-2) positive breast cancer.
• Have completed a course of prior trastuzumab treatment.
• Have a diagnosis of early stage (I, II, III, IIIB, IIIC) primary breast cancer.
• Are not currently receiving chemotherapy, radiation therapy, immunotherapy or biotherapy for breast cancer.

Study participation lasts for up to approximately 5 years. All office visits, study-related medical evaluations, and study drug will be provided to participants at no cost.

Download a PDF of this information here.